TempraMed

Company Overview

Snapshot

Founded in October 2014 by Ron Nagar and Elina Nagar, TempraMed operates with 11–50 employees. The company has raised $10.18M across 6 funding rounds. In October 2025, TempraMed became publicly listed on the Canadian Securities Exchange.

Business overview

TempraMed develops patent-protected technology for temperature control and tracking of medications without external power sources. Its core products, such as the VIVI Cap and VIVI Epi, provide thermal protection for temperature-sensitive injectable medications like insulin, EpiPens, biologics, and hormones. The company serves patients, healthcare providers, and payors globally, operating within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In June 2026, TempraMed signed an exclusive distribution partnership in Brazil, one of the largest diabetes and biologics markets globally. This strategic move signals significant market expansion and validates the company's growth trajectory by securing access to a key international market for its temperature-controlled medication solutions.

Company Intelligence Q&A

What was a significant recent product launch for TempraMed?

In January 2026, TempraMed commercially launched VIVI Med™, a new temperature-protection solution designed to safeguard various temperature-sensitive medications beyond the insulin-pen format, including biologics and GLP-1 therapies.

What strategic partnership did TempraMed establish in February 2026?

In February 2026, TempraMed partnered with FrontrowMD, leading to over 275 clinicians recommending their VIVI Cap product to patients across the United States, strengthening its commercialization strategy.

What was a key development regarding TempraMed's intellectual property in May 2026?

In May 2026, TempraMed announced it was granted an Indian Design Patent for its VIVI Cap Smart Product, strengthening its global intellectual property position.

What was a major commercial milestone for TempraMed in Israel in February 2026?

In February 2026, TempraMed partnered with Super-Pharm, Israel's largest pharmacy chain, to commence a national product rollout strategy, significantly increasing its visibility and consumer reach in the country.

What was the outcome of TempraMed's private placement in January 2026?

In January 2026, TempraMed closed a non-brokered private placement, raising CAD$2,524,836.28 to support its expansion into international markets, secure distribution partnerships, and broaden its product portfolio.